Despite a large number of studies showing survival advantage, lower HIV VL, and higher CD4 in those with HIV and HPgV-1 coinfection, the interpretation of the Amsterdam data continues to reduce acceptance of the apparent beneficial effect of HPgV-1 on HIV survival. This evidence concerns the gene CD4 and coinfection.